4 completed, 2 unknown, 1 active not recruiting, 1 enrolling by invitation. 2 Phase 2, 2 Phase 4, 1 Early Phase 1, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 4 | 2 | Completed 2 |
| Early Phase 1 | 1 | Completed 1 |
| Not applicable | 1 | Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow Rubidium-82: new trials by email Literature Review of Rubidium-82 trials Research Report on Rubidium-82
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Parathyroid Adenoma Detection With Rubidium-82 Imaging PET/CT imaging with rubidium-82 - Parathyroid Adenomas, Hyperparathyroidism, Primary | Enrolling by invitation | Matthieu Pelletier-Galarneau, MD MSc | 20 | 2026-11-01 | 2026-10-27 | |
| Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma 82-Rb injection - Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 50 | 2026-01-01 | 2026-01-16 |
| 18F-mFBG Imaging for Myocardial Sympathetic Innervation 18F-metaFluorobenzylguanidine, Rubidium-82 - Heart Failure, Ischemic Cardiomyopathy | Phase 2 | Recruiting | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) | 20 | 2025-11-05 | 2026-07-01 |
| Dose Optimization for Rubidium PET Imaging in Patients With Known or Suspected Ischemic Heart Disease Rb-82 Radioisotope - Ischemic Heart Disease | Active not recruiting | Ottawa Heart Institute Research Corporation | 48 | 2022-07-01 | 2026-05-12 | |
| Impact of Coronary Artery Stenting on Quantitative Myocardial Blood Flow and Health Status Rubidium-82, Seattle Angina Questionnaire-7, Rose Dyspnea Scale - Coronary Artery Disease | Unknown | Cardiovascular Imaging Technologies | 75 | 2019-12-23 | 2020-07-17 | |
| Spironolactone Therapy in Chronic Stable Right HF Trial Spironolactone, Placebo, PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82 - Chronic Right-Sided Heart Failure, Pulmonary Arterial Hypertension | Phase 4 | Completed | Ottawa Heart Institute Research Corporation | 15 | 2018-04-01 | 2026-05-06 |
| Initial Human Validation of Simultaneous Dual-Tracer Cardiac PET Imaging Cardiac PET scan w/18F-Fluorodeoxyglucose and rubidium-82 - Ischemic Heart Disease, Myocardial Infarction | Early Phase 1 | Completed | University of Michigan | 30 | 2013-12-01 | 2017-02-23 |
| Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation Regadenoson, Rubidium-82 - Myocardial Blood Flow Reserve | Phase 4 | Completed | Timothy M. Bateman, MD | 80 | 2013-07-01 | 2018-08-16 |
| Rubidium-82 PET and Tc-99m-MIBI SPET: A Head to Head Comparison Rubidium-82, Sestamibi. reconstitution with sodium pertechnetate (99mTc) - Coronary Artery Disease | Phase 3 | Completed | Advanced Accelerator Applications | 135 | 2011-02-01 | 2014-05-14 |
| Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer 18F-fluoromisonidazole, fluorescence angiography, laboratory biomarker analysis - Breast Cancer, Colorectal Cancer | Not applicable | Unknown | University College London (UCL) Cancer Institute | 500 | 2006-11-01 | 2013-08-26 |
Coronary Artery Disease (2) · Myocardial Ischemia (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Head and Neck Neoplasms (1) · Heart Failure (1) · Hyperparathyroidism, Primary (1) · Hypertension, Pulmonary (1) · Hypopharyngeal Neoplasms (1) · Laryngeal Neoplasms (1) · Lipodystrophy, Congenital Generalized, Type 3 (1)
Ottawa Heart Institute Research Corporation (2) · Advanced Accelerator Applications (1) · Assistance Publique - Hôpitaux de Paris (1) · Cardiovascular Imaging Technologies (1) · Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) (1) · Matthieu Pelletier-Galarneau, MD MSc (1) · Timothy M. Bateman, MD (1) · University College London (UCL) Cancer Institute (1) · University of Michigan (1)
United States (4) · Canada (3) · United Kingdom (2) · France (1)
K. Lance Gould, MD (1) · Leon Menezes, Dr. (1) · Peter Ell, MD (1) · Timothy M Bateman, MD (1) · Venkatesh L. Murthy, M.D. (1)
2009 (1)